ClinicalTrials.gg
CompletedNCT04167462POETYK-PSO-3Updated Mar 8, 2023Results posted

An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South Korea

A Phase 3 interventional study of BMS-986165 and Placebo in Psoriasis, sponsored by Bristol-Myers Squibb. Completed at 34 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-08.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing deucravacitinib in Psoriasis — 6 open to participants now, 6 under way, 4 of them phase 3. deucravacitinib · Psoriasis.

Enrollment
9th of 26
220 · median 102
Started
2019
with 3 others
Phase 3
9 of 26
4 open now
Registered
11th of 26
by date
Lead sponsor
18 of 26
Bristol-Myers Squibb

Among the 26 studies testing deucravacitinib in Psoriasis, this one is the 9th largest by enrollment, is one of 4 that started in 2019, is one of 9 in phase 3, and was the 11th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

6 of the 26 studies testing deucravacitinib in Psoriasis are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About deucravacitinib

deucravacitinib: first FDA approval 2022 (SOTYKTU), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing deucravacitinib in Psoriasis, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo in participants with moderate to severe plaque psoriasis in mainland China, Taiwan, and South Korea

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Plaque psoriasis for at least 6 months
  • Moderate to severe disease
  • Candidate for phototherapy or systemic therapy

Exclusion criteria

Exclusion Criteria:

  • Other forms of psoriasis
  • History of recent infection
  • Prior exposure to BMS-986165

Other inclusion/exclusion criteria may apply.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
220 participants (actual)

Study arms

  • Experimental
    Arm A:BMS-986165 oral administration

    Drug: BMS-986165

  • Placebo comparator
    Arm B: Placebo oral administration

    Other: Placebo

Interventions

  • Specified dose on Specified Days

  • OtherPlacebo

    Specified dose on Specified days

06

What researchers measure

Primary outcomes

  1. The Percentage of Participants With sPGA Response of 0 or 1

    static Physician Global Assessment (sPGA) 0 or 1 response assessed as a percentage of participants with a sPGA score of 0 or 1 as assessed at week 16 with at least a 2-point improvement from baseline. The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scale, and induration. The sPGA measure determines psoriasis severity at a single point in time (without taking into account the baseline disease condition) as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). A higher score equates to higher severity of disease. The individual scores at each visit will range from 0-4 and will be captured for erythema, induration, and scaling. A total score will also be computed based on the average of the 3 characteristic scores. The average score will be rounded to the nearest whole number and data for this endpoint will be derived from the total average score.

    Time frame: At week 16

  2. The Percentage of Participants With PASI 75 Response

    Psoriasis Area and Severity Index (PASI) 75 response is an assessment defined as the percentage of participants who experience at least a 75% improvement in PASI score at Week 16 as compared with baseline value. PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions graded on a scale from 0-4 (0= absent symptoms, 1= mild symptoms, 2= moderate symptoms, 3= severe symptoms, 4= very severe symptoms), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. The PASI includes multiple subscores and a final total score. Individual plaque characteristic rating scores are provided for each body region as well as the weighted score. The PASI Total score will be used to assess response to treatment.

    Time frame: At week 16

Secondary outcomes

  1. The Percentage of Participants With PASI 90 Response

    Psoriasis Area and Severity Index (PASI) 90 response is an assessment defined as the percentage of participants who experience at least a 90% improvement in PASI score at Week 16 as compared with baseline value. PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions graded on a scale from 0-4 (0= absent symptoms, 1= mild symptoms, 2= moderate symptoms, 3= severe symptoms, 4= very severe symptoms), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. The PASI includes multiple subscores and a final total score. Individual plaque characteristic rating scores are provided for each body region as well as the weighted score. The PASI Total score will be used to assess response to treatment.

    Time frame: At week 16

  2. The Percentage of Participants With PASI 100 Response

    Psoriasis Area and Severity Index (PASI) 100 response is an assessment defined as the percentage of participants who experience at least a 100% improvement in PASI score at Week 16 as compared with baseline value. PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions graded on a scale from 0-4 (0= absent symptoms, 1= mild symptoms, 2= moderate symptoms, 3= severe symptoms, 4= very severe symptoms), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. The PASI includes multiple subscores and a final total score. Individual plaque characteristic rating scores are provided for each body region as well as the weighted score. The PASI Total score will be used to assess response to treatment.

    Time frame: At week 16

  3. The Percentage of Participants With sPGA 0 Response

    static Physician Global Assessment (sPGA) 0 response is defined as the percentage of participants with a sPGA score of 0 with at least 2-point improvement from baseline as assessed at Week 16. The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scale, and induration. The sPGA measure determines psoriasis severity at a single point in time (without taking into account the baseline disease condition) as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). A higher score equates to higher severity of disease. The individual scores at each visit will range from 0-4 and will be captured for erythema, induration, and scaling. A total score will also be computed based on the average of the 3 characteristic scores. The average score will be rounded to the nearest whole number and data for this endpoint will be derived from the total average score.

    Time frame: At week 16

  4. Change From Baseline in PSSD Symptom Score

    Change from baseline in Psoriasis Symptoms and Signs Diary (PSSD) symptom score is defined as the percentage of participants with a PSSD score of 0 among participants with a baseline PSSD symptom score ≥ 1. The PSSD is an 11-item participant-reported instrument that assesses severity of symptoms and participant-observed signs commonly associated in plaque psoriasis. The PSSD assesses severity of 5 symptoms (itch, pain, stinging, burning, skin tightness) and 6 participant-observed signs (skin dryness, cracking, scaling, shedding or flaking, redness, bleeding) using 0-10 numerical ratings. The severity of each item is rated on an 11-point numeric rating scale ranging from 0 (absent) to 10 (worst imaginable). A symptom score will be derived by averaging the 5 questions and multiplying by 10. A sign score will be derived by averaging the 6 questions and multiplying by 10. A total PSSD score with range 0-100 will be derived from taking the average of the symptom and sign scores.

    Time frame: Baseline and at Week 16

  5. The Percentage of Participants With Ss-PGA Score of 0 or 1

    Scalp specific Physician's Global Assessment (ss-PGA) 0 or 1 assessed at Week 16 as a percentage of participants with a ss-PGA score 0 or 1 among participants with a baseline ss-PGA score ≥3. The ss-PGA is assessed at each visit throughout the study in participants that have evidence of scalp psoriasis at baseline. If there is evidence of scalp involvement, scalp lesions are evaluated in terms of clinical signs of redness, thickness, and scaliness and scored on the following 5-point ss-PGA scale: 0 = absence of disease, 1 = very mild disease, 2 = mild disease, 3 = moderate disease, 4 = severe disease.

    Time frame: At week 16

  6. The Percentage of Participants With DLQI Score of 0 or 1

    Dermatology Life Quality Index 0 or 1 assessed at Week 16 as a percentage of participants with a DLQI score of 0 or 1 among participants with a baseline DLQI score ≥2. The DLQI is a participant-reported quality of life index which consists of 10 questions concerning symptoms and feelings, daily activities, leisure, work, school, personal relationships, and treatment during the last week. Each question is scored on a scale of 0 to 3 where a higher value signifies higher severity, with 0="not at all", 1="a little", 2="a lot", or 3="very much". The scores are summed, giving a range from 0 (no impairment of life quality) to 30 (maximum impairment). Interpretation of DLQI scores is as follows: 1. 0-1 = no effect at all on participant's life 2. 2-5 = small effect on participant's life 3. 6-10 = moderate effect on participant's life 4. 11-20 = very large effect on participant's life 5. 21-30 = extremely large effect on participant's life

    Time frame: At week 16

  7. The Percentage of Participants With PGA-F Score of 0 or 1

    Physician's Global Assessment of Fingernail Psoriasis (PGA-F) score of 0 or 1 assessed at Week 16 as a percentage of participants with a PGA-F score of 0 or 1 with at least a 2-point improvement from baseline among participants with a baseline PGA-F score ≥3. If a participant shows evidence of psoriatic fingernail involvement, the assessment will be performed at each subsequent visit to assess severity and improvement over time. Only participants with a PGA-F score at baseline will be assessed throughout the study. The overall condition of the fingernails is rated on a 5-point scale: 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, and 4 = severe

    Time frame: At week 16

  8. The Percentage of Participants With PSSD Symptom Score of 0

    Psoriasis Symptoms and Signs Diary (PSSD) symptom score of 0 assessed as a percentage of participants with a PSSD symptom score of 0 among participants with a baseline PSSD symptom score ≥1. The PSSD is an 11-item participant-reported instrument that assesses severity of symptoms and participant-observed signs commonly associated in plaque psoriasis. The PSSD assesses severity of 5 symptoms (itch, pain, stinging, burning, skin tightness) and 6 participant-observed signs (skin dryness, cracking, scaling, shedding or flaking, redness, bleeding) using 0-10 numerical ratings. The severity of each item is rated on an 11-point numeric rating scale ranging from 0 (absent) to 10 (worst imaginable). A symptom score will be derived by averaging the 5 questions included in the symptom score and multiplying by 10. scores range from 0-100, where 0 representing the least severe symptom and 100 the most severe.

    Time frame: At week 16

  9. The Percentage of Participants With Pp-PGA Score of 0 or 1

    Palmoplantar PGA (pp-PGA) 0/1 assessed as a percentage of participants with a pp-PGA score of 0 or 1 among participants with a baseline pp-PGA score ≥3. This measure will be used for participants with palmoplantar (finger and toe surfaces) involvement at baseline. Only participants with baseline palmoplantar involvement will continue to have these assessments at each subsequent visit throughout the study. The pp-PGA uses a 5-point (0-4) overall severity scale: 0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; and 4 = severe.

    Time frame: At week 16

  10. The Percentage of Participants With PASI 75 Response at Week 52

    Psoriasis Area and Severity Index (PASI) 75 response is an assessment defined as the percentage of participants who experience at least a 75% improvement in PASI score at Week 52 as compared with participants that are PASI 75 responders at Week 16. PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions graded on a scale from 0-4 (0= absent symptoms, 1= mild symptoms, 2= moderate symptoms, 3= severe symptoms, 4= very severe symptoms), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. The PASI includes multiple subscores and a final total score. Individual plaque characteristic rating scores are provided for each body region as well as the weighted score. The PASI Total score will be used to assess response to treatment.

    Time frame: At week 52

  11. The Percentage of Participants With sPGA Response of 0 or 1 at Week 52

    static Physician Global Assessment (sPGA) 0 or 1 response assessed as a percentage of participants with a sPGA score of 0 or 1 as assessed at week 52 among participants that are sPGA 0 or 1 responders at Week 16. The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scale, and induration. The sPGA measure determines psoriasis severity at a single point in time (without taking into account the baseline disease condition) as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). A higher score equates to higher severity of disease. The individual scores at each visit will range from 0-4 and will be captured for erythema, induration, and scaling. A total score will also be computed based on the average of the 3 characteristic scores. The average score will be rounded to the nearest whole number and data for this endpoint will be derived from the total average score.

    Time frame: At week 52

07

Results

Posted Nov 2, 2022

Participant flow

Participant flow — Overall Study
MilestoneArm 1: BMS-986165Arm 2: Placebo
Started14674
Completed13264
Not completed1410
Withdrew: Other reasons32
Withdrew: Withdrawal by subject67
Withdrew: Adverse event40
Withdrew: Pregnancy10
Withdrew: Lack of efficacy01

Outcome measures

PrimaryThe Percentage of Participants With sPGA Response of 0 or 1

static Physician Global Assessment (sPGA) 0 or 1 response assessed as a percentage of participants with a sPGA score of 0 or 1 as assessed at week 16 with at least a 2-point improvement from baseline. The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scale, and induration. The sPGA measure determines psoriasis severity at a single point in time (without taking into account the baseline disease condition) as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). A higher score equates to higher severity of disease. The individual scores at each visit will range from 0-4 and will be captured for erythema, induration, and scaling. A total score will also be computed based on the average of the 3 characteristic scores. The average score will be rounded to the nearest whole number and data for this endpoint will be derived from the total average score.

Time frame:
At week 16
Reported as:
Number · Percentage of participants
The Percentage of Participants With sPGA Response of 0 or 1
Percentage of participantsArm 1: BMS-986165Arm 2: Placebo
The Percentage of Participants With sPGA Response of 0 or 155.6 (47.4 to 63.7)6.8 (1.0 to 12.5)
Statistical analysis
  • Arm 1: BMS-986165 vs Arm 2: Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 16.49 · 95% CI 6.33 to 42.98
PrimaryThe Percentage of Participants With PASI 75 Response

Psoriasis Area and Severity Index (PASI) 75 response is an assessment defined as the percentage of participants who experience at least a 75% improvement in PASI score at Week 16 as compared with baseline value. PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions graded on a scale from 0-4 (0= absent symptoms, 1= mild symptoms, 2= moderate symptoms, 3= severe symptoms, 4= very severe symptoms), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. The PASI includes multiple subscores and a final total score. Individual plaque characteristic rating scores are provided for each body region as well as the weighted score. The PASI Total score will be used to assess response to treatment.

Time frame:
At week 16
Reported as:
Number · Percentage of participants
The Percentage of Participants With PASI 75 Response
Percentage of participantsArm 1: BMS-986165Arm 2: Placebo
The Percentage of Participants With PASI 75 Response68.8 (61.2 to 76.3)8.1 (1.9 to 14.3)
Statistical analysis
  • Arm 1: BMS-986165 vs Arm 2: Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 24.29 · 95% CI 9.60 to 61.46
SecondaryThe Percentage of Participants With PASI 90 Response

Psoriasis Area and Severity Index (PASI) 90 response is an assessment defined as the percentage of participants who experience at least a 90% improvement in PASI score at Week 16 as compared with baseline value. PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions graded on a scale from 0-4 (0= absent symptoms, 1= mild symptoms, 2= moderate symptoms, 3= severe symptoms, 4= very severe symptoms), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. The PASI includes multiple subscores and a final total score. Individual plaque characteristic rating scores are provided for each body region as well as the weighted score. The PASI Total score will be used to assess response to treatment.

Time frame:
At week 16
Reported as:
Number · Percentage of participants
The Percentage of Participants With PASI 90 Response
Percentage of participantsArm 1: BMS-986165Arm 2: Placebo
The Percentage of Participants With PASI 90 Response38.2 (30.3 to 46.1)1.4 (0.0 to 4.0)
Statistical analysis
  • Arm 1: BMS-986165 vs Arm 2: Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 41.19 · 95% CI 5.82 to 291.26
SecondaryThe Percentage of Participants With PASI 100 Response

Psoriasis Area and Severity Index (PASI) 100 response is an assessment defined as the percentage of participants who experience at least a 100% improvement in PASI score at Week 16 as compared with baseline value. PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions graded on a scale from 0-4 (0= absent symptoms, 1= mild symptoms, 2= moderate symptoms, 3= severe symptoms, 4= very severe symptoms), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. The PASI includes multiple subscores and a final total score. Individual plaque characteristic rating scores are provided for each body region as well as the weighted score. The PASI Total score will be used to assess response to treatment.

Time frame:
At week 16
Reported as:
Number · Percentage of participants
The Percentage of Participants With PASI 100 Response
Percentage of participantsArm 1: BMS-986165Arm 2: Placebo
The Percentage of Participants With PASI 100 Response4.2 (0.9 to 7.4)0 (0 to 0)
SecondaryThe Percentage of Participants With sPGA 0 Response

static Physician Global Assessment (sPGA) 0 response is defined as the percentage of participants with a sPGA score of 0 with at least 2-point improvement from baseline as assessed at Week 16. The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scale, and induration. The sPGA measure determines psoriasis severity at a single point in time (without taking into account the baseline disease condition) as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). A higher score equates to higher severity of disease. The individual scores at each visit will range from 0-4 and will be captured for erythema, induration, and scaling. A total score will also be computed based on the average of the 3 characteristic scores. The average score will be rounded to the nearest whole number and data for this endpoint will be derived from the total average score.

Time frame:
At week 16
Reported as:
Number · Percentage of participants
The Percentage of Participants With sPGA 0 Response
Percentage of participantsArm 1: BMS-986165Arm 2: Placebo
The Percentage of Participants With sPGA 0 Response13.9 (8.2 to 19.5)0 (0 to 0)
SecondaryChange From Baseline in PSSD Symptom Score

Change from baseline in Psoriasis Symptoms and Signs Diary (PSSD) symptom score is defined as the percentage of participants with a PSSD score of 0 among participants with a baseline PSSD symptom score ≥ 1. The PSSD is an 11-item participant-reported instrument that assesses severity of symptoms and participant-observed signs commonly associated in plaque psoriasis. The PSSD assesses severity of 5 symptoms (itch, pain, stinging, burning, skin tightness) and 6 participant-observed signs (skin dryness, cracking, scaling, shedding or flaking, redness, bleeding) using 0-10 numerical ratings. The severity of each item is rated on an 11-point numeric rating scale ranging from 0 (absent) to 10 (worst imaginable). A symptom score will be derived by averaging the 5 questions and multiplying by 10. A sign score will be derived by averaging the 6 questions and multiplying by 10. A total PSSD score with range 0-100 will be derived from taking the average of the symptom and sign scores.

Time frame:
Baseline and at Week 16
Reported as:
Mean · Score on a scale
Change From Baseline in PSSD Symptom Score
Score on a scaleArm 1: BMS-986165Arm 2: Placebo
Change From Baseline in PSSD Symptom Score-29.4 ± 23.21-1.8 ± 25.32
SecondaryThe Percentage of Participants With Ss-PGA Score of 0 or 1

Scalp specific Physician's Global Assessment (ss-PGA) 0 or 1 assessed at Week 16 as a percentage of participants with a ss-PGA score 0 or 1 among participants with a baseline ss-PGA score ≥3. The ss-PGA is assessed at each visit throughout the study in participants that have evidence of scalp psoriasis at baseline. If there is evidence of scalp involvement, scalp lesions are evaluated in terms of clinical signs of redness, thickness, and scaliness and scored on the following 5-point ss-PGA scale: 0 = absence of disease, 1 = very mild disease, 2 = mild disease, 3 = moderate disease, 4 = severe disease.

Time frame:
At week 16
Reported as:
Number · Percentage of participants
The Percentage of Participants With Ss-PGA Score of 0 or 1
Percentage of participantsArm 1: BMS-986165Arm 2: Placebo
The Percentage of Participants With Ss-PGA Score of 0 or 162.9 (53.6 to 72.1)9.8 (1.6 to 18.0)
Statistical analysis
  • Arm 1: BMS-986165 vs Arm 2: Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 17.27 · 95% CI 6.06 to 49.25
SecondaryThe Percentage of Participants With DLQI Score of 0 or 1

Dermatology Life Quality Index 0 or 1 assessed at Week 16 as a percentage of participants with a DLQI score of 0 or 1 among participants with a baseline DLQI score ≥2. The DLQI is a participant-reported quality of life index which consists of 10 questions concerning symptoms and feelings, daily activities, leisure, work, school, personal relationships, and treatment during the last week. Each question is scored on a scale of 0 to 3 where a higher value signifies higher severity, with 0="not at all", 1="a little", 2="a lot", or 3="very much". The scores are summed, giving a range from 0 (no impairment of life quality) to 30 (maximum impairment). Interpretation of DLQI scores is as follows: 1. 0-1 = no effect at all on participant's life 2. 2-5 = small effect on participant's life 3. 6-10 = moderate effect on participant's life 4. 11-20 = very large effect on participant's life 5. 21-30 = extremely large effect on participant's life

Time frame:
At week 16
Reported as:
Number · Percentage of participants
The Percentage of Participants With DLQI Score of 0 or 1
Percentage of participantsArm 1: BMS-986165Arm 2: Placebo
The Percentage of Participants With DLQI Score of 0 or 136.4 (28.5 to 44.4)11.6 (4.0 to 19.1)
Statistical analysis
  • Arm 1: BMS-986165 vs Arm 2: Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 5.10 · 95% CI 2.19 to 11.91
SecondaryThe Percentage of Participants With PGA-F Score of 0 or 1

Physician's Global Assessment of Fingernail Psoriasis (PGA-F) score of 0 or 1 assessed at Week 16 as a percentage of participants with a PGA-F score of 0 or 1 with at least a 2-point improvement from baseline among participants with a baseline PGA-F score ≥3. If a participant shows evidence of psoriatic fingernail involvement, the assessment will be performed at each subsequent visit to assess severity and improvement over time. Only participants with a PGA-F score at baseline will be assessed throughout the study. The overall condition of the fingernails is rated on a 5-point scale: 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, and 4 = severe

Time frame:
At week 16
Reported as:
Number · Percentage of participants
The Percentage of Participants With PGA-F Score of 0 or 1
Percentage of participantsArm 1: BMS-986165Arm 2: Placebo
The Percentage of Participants With PGA-F Score of 0 or 119.6 (8.1 to 31.0)4.2 (0.0 to 12.2)
Statistical analysis
  • Arm 1: BMS-986165 vs Arm 2: Placebo · Cochran-Mantel-Haenszel · p = 0.0947 · Odds ratio (or): 5.86 · 95% CI 0.64 to 53.28
SecondaryThe Percentage of Participants With PSSD Symptom Score of 0

Psoriasis Symptoms and Signs Diary (PSSD) symptom score of 0 assessed as a percentage of participants with a PSSD symptom score of 0 among participants with a baseline PSSD symptom score ≥1. The PSSD is an 11-item participant-reported instrument that assesses severity of symptoms and participant-observed signs commonly associated in plaque psoriasis. The PSSD assesses severity of 5 symptoms (itch, pain, stinging, burning, skin tightness) and 6 participant-observed signs (skin dryness, cracking, scaling, shedding or flaking, redness, bleeding) using 0-10 numerical ratings. The severity of each item is rated on an 11-point numeric rating scale ranging from 0 (absent) to 10 (worst imaginable). A symptom score will be derived by averaging the 5 questions included in the symptom score and multiplying by 10. scores range from 0-100, where 0 representing the least severe symptom and 100 the most severe.

Time frame:
At week 16
Reported as:
Number · Percentage of participants
The Percentage of Participants With PSSD Symptom Score of 0
Percentage of participantsArm 1: BMS-986165Arm 2: Placebo
The Percentage of Participants With PSSD Symptom Score of 04.9 (1.4 to 8.5)1.4 (0.0 to 4.0)
Statistical analysis
  • Arm 1: BMS-986165 vs Arm 2: Placebo · Cochran-Mantel-Haenszel · p = 0.1741 · Odds ratio (or): 4.11 · 95% CI 0.47 to 35.74
SecondaryThe Percentage of Participants With Pp-PGA Score of 0 or 1

Palmoplantar PGA (pp-PGA) 0/1 assessed as a percentage of participants with a pp-PGA score of 0 or 1 among participants with a baseline pp-PGA score ≥3. This measure will be used for participants with palmoplantar (finger and toe surfaces) involvement at baseline. Only participants with baseline palmoplantar involvement will continue to have these assessments at each subsequent visit throughout the study. The pp-PGA uses a 5-point (0-4) overall severity scale: 0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; and 4 = severe.

Time frame:
At week 16
Reported as:
Number · Percentage of participants
The Percentage of Participants With Pp-PGA Score of 0 or 1
Percentage of participantsArm 1: BMS-986165Arm 2: Placebo
The Percentage of Participants With Pp-PGA Score of 0 or 166.7 (42.8 to 90.5)0 (0 to 0)
SecondaryThe Percentage of Participants With PASI 75 Response at Week 52

Psoriasis Area and Severity Index (PASI) 75 response is an assessment defined as the percentage of participants who experience at least a 75% improvement in PASI score at Week 52 as compared with participants that are PASI 75 responders at Week 16. PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions graded on a scale from 0-4 (0= absent symptoms, 1= mild symptoms, 2= moderate symptoms, 3= severe symptoms, 4= very severe symptoms), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. The PASI includes multiple subscores and a final total score. Individual plaque characteristic rating scores are provided for each body region as well as the weighted score. The PASI Total score will be used to assess response to treatment.

Time frame:
At week 52
Reported as:
Number · Percentage of participants
The Percentage of Participants With PASI 75 Response at Week 52
Percentage of participantsArm 1: BMS-986165Arm 2: Placebo
The Percentage of Participants With PASI 75 Response at Week 5271.0 (63.7 to 78.4)70.3 (59.9 to 80.7)
SecondaryThe Percentage of Participants With sPGA Response of 0 or 1 at Week 52

static Physician Global Assessment (sPGA) 0 or 1 response assessed as a percentage of participants with a sPGA score of 0 or 1 as assessed at week 52 among participants that are sPGA 0 or 1 responders at Week 16. The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scale, and induration. The sPGA measure determines psoriasis severity at a single point in time (without taking into account the baseline disease condition) as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). A higher score equates to higher severity of disease. The individual scores at each visit will range from 0-4 and will be captured for erythema, induration, and scaling. A total score will also be computed based on the average of the 3 characteristic scores. The average score will be rounded to the nearest whole number and data for this endpoint will be derived from the total average score.

Time frame:
At week 52
Reported as:
Number · Percentage of participants
The Percentage of Participants With sPGA Response of 0 or 1 at Week 52
Percentage of participantsArm 1: BMS-986165Arm 2: Placebo
The Percentage of Participants With sPGA Response of 0 or 1 at Week 5251.0 (42.9 to 59.2)52.7 (41.3 to 64.1)

Adverse events

Collected over SAEs and NSAEs: From first dose to 100 days post last dose (up to approximately 15 months). All-Cause Mortality: From first dose through the course of the trial (up to approximately 24 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Week 0 up to Week 160/74 (0%)3/74 (4.1%)29/74 (39.2%)
BMS-986165 Week 0 up to Week 520/146 (0%)4/146 (2.7%)55/146 (37.7%)
BMS-986165 Week 16 up to Week 520/68 (0%)0/68 (0%)19/68 (27.9%)
Most frequent serious events
Most frequent serious events
EventPlacebo Week 0 up to Week 16BMS-986165 Week 0 up to Week 52BMS-986165 Week 16 up to Week 52
CystGeneral disorders1/740/1460/68
Comminuted fractureInjury, poisoning and procedural complications1/740/1460/68
Tonsillar hypertrophyRespiratory, thoracic and mediastinal disorders1/740/1460/68
CholecystitisHepatobiliary disorders0/741/1460/68
GastroenteritisInfections and infestations0/741/1460/68
Gastroenteritis shigellaInfections and infestations0/741/1460/68
Accidental overdoseInjury, poisoning and procedural complications0/741/1460/68
Hepatobiliary procedural complicationInjury, poisoning and procedural complications0/741/1460/68
Most frequent other events
Most frequent other events
EventPlacebo Week 0 up to Week 16BMS-986165 Week 0 up to Week 52BMS-986165 Week 16 up to Week 52
Upper respiratory tract infectionInfections and infestations14/7426/1464/68
PsoriasisSkin and subcutaneous tissue disorders2/744/1468/68
NasopharyngitisInfections and infestations6/7410/1464/68
Mouth ulcerationGastrointestinal disorders4/7411/1460/68
Psoriatic arthropathyMusculoskeletal and connective tissue disorders0/742/1464/68
HeadacheNervous system disorders0/748/1464/68
FolliculitisInfections and infestations4/745/1461/68
PharyngitisInfections and infestations4/742/1461/68

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Arm 1: BMS-986165Arm 2: PlaceboTotal
Mean40.3 ± 12.1941.2 ± 12.3340.6 ± 12.22
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1: BMS-986165Arm 2: PlaceboTotal
Female231740
Male12357180
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Arm 1: BMS-986165Arm 2: PlaceboTotal
Asian - Chinese11862180
Asian - Korean281240
08

Study locations

34 sites
  • Local Institution - 0001
    Beijing, Beijing 100044, China
  • Local Institution - 0007
    Beijing, Beijing 100050, China
  • Local Institution - 0014
    Beijing, Beijing 100069, China
  • Local Institution - 0008
    Chongqing, Chongqing 630014, China
  • Local Institution - 0011
    Wuhan, Hubei 430022, China
  • Local Institution - 0016
    Wuhan, Hubei 430030, China
  • Local Institution
    Changsha, Hunan 410011, China
  • Local Institution
    Nanjing, Jiangsu 210029, China
  • Local Institution - 0002
    Changchun, Jilin 130021, China
  • Local Institution - 0006
    Dalian, Liaoning 116011, China
  • Local Institution - 0018
    Taiyuan, Shan1xi 030001, China
  • Local Institution - 0012
    Jingan, Shanghai 200443, China
  • Local Institution
    Chengdu, Sichuan 610041, China
  • Local Institution - 0009
    Hangzhou, Zhejiang 310003, China
  • Local Institution - 0003
    Hangzhou, Zhejiang 310014, China
  • Local Institution - 0004
    Hangzhou, Zhejiang 310016, China
  • Local Institution - 0034
    Bucheon-si, 14584, Korea, Republic of
  • Local Institution - 0033
    Goyang-si, 10380, Korea, Republic of
  • Local Institution - 0028
    Gwangju, 61469, Korea, Republic of
  • Local Institution - 0035
    Incheon, 21565, Korea, Republic of
  • Local Institution - 0022
    Seongnam-si, 13496, Korea, Republic of
  • Local Institution - 0037
    Seongnam-si, 13620, Korea, Republic of
  • Local Institution - 0020
    Seoul., 06973, Korea, Republic of
  • Local Institution - 0036
    Seoul, 02447, Korea, Republic of
  • Local Institution - 0026
    Seoul, 03080, Korea, Republic of
  • Local Institution
    Seoul, 03722, Korea, Republic of
  • Local Institution - 0021
    Seoul, 05030, Korea, Republic of
  • Local Institution - 0027
    Seoul, 08308, Korea, Republic of
  • Local Institution - 0024
    Seoul, 137-701, Korea, Republic of
  • Local Institution - 0023
    Suwon, 16499, Korea, Republic of
  • Local Institution - 0029
    Kaohsiung, 83301, Taiwan
  • Local Institution - 0031
    Taipei, 10002, Taiwan
  • Local Institution - 0032
    Taipei, 11490, Taiwan
  • Local Institution - 0025
    Taoyuan, 33305, Taiwan
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2019 to primary completion in Mar 2021, 15 months.

Results were first posted in Nov 2022, 1 year 7 months after primary completion. A results delay was requested in Mar 2022.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 15 months is close to that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2019
First posted
Nov 18, 2019
StartActual
Nov 25, 2019
Primary completionActual
Mar 8, 2021
CompletionActual
Jan 7, 2022
Results delay requested
Mar 7, 2022
Results first posted
Nov 2, 2022
Last update
Mar 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04167462
Responsible party
Sponsor
First posted
Nov 18, 2019
Start date
Nov 25, 2019
Primary completion
Mar 8, 2021
Completion
Jan 7, 2022
Results posted
Nov 2, 2022
Last update
Mar 8, 2023

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deucravacitinib

Start the discussion